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We present a method to fit a mixed effects Cox model with interval-censored data. Our proposal is based on
a multiple imputation approach that uses the truncated Weibull distribution to replace the interval-censored
data by imputed survival times and then uses established mixed effects Cox methods for right-censored data.
Interval-censored data were encountered in a database corresponding to a recompilation of retrospective data
from eight Analytical Treatment Interruption (ATI) studies in 158 HIV-positive combination antiretroviral
treatment (cART)-suppressed individuals. The main variable of interest is the time to viral rebound, which
is defined as the increase of serum viral load to detectable levels in a patient with previously undetectable
viral load, as a consequence of the interruption of cART. Another aspect of interest of the analysis is to
consider the fact that the data come from different studies based on different grounds and that we have
several assessments on the same patient. In order to handle this extra variability, we frame the problem
into a mixed effects Cox model that considers a random intercept per subject as well as correlated random
intercept and slope for pre-cART viral load per study. Our procedure has been implemented in R using two
packages: truncdist and coxme, and can be applied to any data set that presents both interval-censored
survival times and a grouped data structure that could be treated as a random effect in a regression model.
The properties of the parameter estimators obtained with our proposed method are addressed through a
simulation study.
Key words: HIV studies; Interval censoring; Mixed effects Cox model; Multiple imputation;
Survival analysis
1 Introduction
Most statistical methods developed for the analysis of survival data assume that the event that defines time
origin is known and allow the event of interest ε that determines failure and, hence, the survival time, to
be right-censored. In many situations, however, the event of interest ε cannot be observed and it is only
known to have occurred within two random times, say L and R. In this set-up, we say that the time to ε,
T , is interval-censored.
Interval-censored data often arises in medical or health studies that entail periodic follow-ups, and
many clinical trials and longitudinal studies fall into this category (Sun, 2007). In such situations, interval-
censored data may arise in several ways. For instance, an HIV-infected patient is examined weekly to
check if his/her viral load exceeds a certain threshold. Suppose that in a first measurement, at time t1, it
does not exceed the threshold and it does in a second measurement at time t2. Hence, all that is known is
that the viral load exceeded the threshold within the interval (t1, t2], but the exact time of viral rebound is
unknown.
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We have encountered interval-censored data while studying the immunological response of HIV posi-
tive patients by means of different parameters of viral rebound dynamics within eight different Analytical
Treatment Interruption (ATI) studies (Leal et al., 2017).
We start introducing the main concepts related to HIV-ATI studies to facilitate reading and understand-
ing of the study that motivates this paper. The Human Immunodeficiency Virus (HIV) is a virus that infects
cells of the immune system, destroying or impairing their function. Infection with the virus results in a
progressive deterioration of the immune system, leading to immune deficiency, and the immune system is
considered deficient if it is no longer able to fulfil its role of fighting infection and disease (World Health
Organization, 2017). HIV-infected patients are generally treated with a combination of antiretroviral drugs
known as combination Antiretroviral Therapy (cART) in order to maximally suppress the HIV virus and
stop the progression to the Acquired Immune Deficiency Syndrome (AIDS).
The Analytical Treatment Interruption (ATI) is a controlled interruption of the cART in HIV-positive
patients and appears in different interventional or observational studies in this field. The objective of
this interruption is the evaluation of the immunological response of the patients, described by different
parameters related to the viral rebound dynamics (Treasure et al., 2016). In the case of our data set,
depending on the study, a single ATI episode or several episodes are studied. Studies including more than
one ATI episode are based on the ‘autovaccination’ theory, according to which repeated encounters of
the immune system with the antigenic stimulus (the virus) will be able to increase the specific immune
response, leading to a major control of the posterior viral load (Graziani & Angel, 2015). The endpoint
of interest in these studies is the time until viral rebound, which is defined as the first time that an HIV-
infected patient, with previously undetectable serum viral load, surpasses the threshold of 20 copies/mL
(or 1.30 in log10 scale). Viral load values lower than 20 copies/mL were considered undetectable when
calculating time to rebound.
Previous to the start of cART, most of the patients in our data set had a high viral load, referred as
pre-cART viral load. As soon as they start cART, the viral load drops down to undetectable levels. In our
case, at the beginning of the first ATI episode (week 0), all patients presented undetectable levels of viral
load. From that moment, the viral load was measured once every week and the corresponding ATI episode
was stopped as soon as the viral load was detectable again; see Figure 1.
To study viral rebound dynamics, we were interested in characterizing the percentiles of the time to
viral load rebound based on the corresponding distribution function, in establishing differences between
male and female patients, in determining the importance of pre-cART VL in suffering a viral rebound,
and in assessing relative risks by means of hazard ratios based on a Cox proportional hazards model (Cox,
1972). To provide rigorous answers to all these issues, several nonparametric and parametric methods for
interval-censored data have been developed and the literature is already abundant, see Go´mez et al. (2009)
for a thorough overview. Finkelstein (1986) was among the first authors to adapt the Cox model to interval-
censored data. Nowadays, parameter estimation in the presence of interval-censored data can be carried
out in R (R Core Team, 2018) by means of the icenReg package (Anderson-Bergman, 2017).
However, the ATI data set not only has interval-censored times to viral rebound but these are also
quite heterogeneous because they correspond to eight different studies that are based on different grounds.
Moreover, several patients underwent more than one treatment interruption. A proper data analysis should
take this into account. Since the variability of measurements in different individuals is usually larger than
the variability between measurements in the same individual (Bland & Altman, 1994), a possible way to
account for this extra variability could be to frame the problem into a mixed effects Cox model where a
grouping variable corresponding to the subject would be added as random effect.
In the case of data coming from different studies, we might have two different scenarios. If there is
homogeneity of the observed effect for some particular covariate, a single measure would be adequate to
describe the general results. If, on the contrary, heterogeneity of effects is found, we should add a random
effect of this covariate per study to capture this heterogeneity and carefully interpret the results. Our ATI
data set falls in the second situation because of the different treatments used (combination of different
drugs or different vaccines) and the different recruitment criteria for patients (such as early or late stage of
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Figure 1 Viral load dynamics during (cART) and the first ATI episode. The last measure before starting
the cART is denoted by pre-cART viral load (VL). In this case, the ATI stopped at week 2 because of
detection of viral rebound.
HIV infection, CD4 count, viral load threshold, among others). Therefore, it is very likely to have some
degree of variation (heterogeneity) among these studies, and for this reason, a random intercept and slope
for pre-cART VL per study is considered.
Some other reasons to consider the inclusion of random effects are similar to those considered by Ya-
maguchi et al. (2002) and Senn (1998), who in the analyses of multicenter trials used random effects to
model the center’s effect variability. As Senn discusses, if we are interested in making inferences about
patients from a given study, the fixed effect approach leaves little alternative but to use the results from that
study only. The random effects approach will allow us to combine information with the given study with
information from all the studies in a way which is more appealing and useful.
In the context of survival analysis, a mixed (fixed and random) effects Cox model with right-censored
data has been presented by Therneau & Grambsch (2000) and its fit is accomplished with the coxme
package of the same author (Therneau, 2018b). However, to the best of our knowledge, a mixed effects
Cox model with interval-censored data has not been studied. Hence, our objective consists of developing
a mixed effects Cox model with interval-censored data in order to correctly model the heterogeneity in our
data set attributable to the repeated measures per patient and the different inclusion criteria per study.
A natural solution to the difficulties of direct estimation based on interval-censored data is to use an
algorithm based on treating the interval-censored observations as missing data and imputing values for
them, thus creating right-censored and exact data (Bebchuk & Betensky, 2000). Interval-censored data
are actually incomplete data, not missing data, because the observed interval provides some information
about the variable of interest (Sun, 2007). Nevertheless, we can still treat the underlying, unobserved true
interval-censored failure times as missing and replace them by imputed times conditional on the observed
information. Using the methodology and software already developed for right-censored data (Therneau,
2018b), our proposal is based on a multiple imputation approach using the truncated Weibull distribution
to replace the censoring intervals by imputed survival times. Our idea is similar to the one of Satten et al.
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(1998) in the case of the Cox model without random effects, who used imputation methods to replace the
interval-censored survival times by imputed values. The authors propose the use of a parametric model for
the baseline hazard in order to generate imputed failure times; following, a rank-based procedure based on
the imputed failure times is used to estimate the regression coefficients.
Multiple imputation is a statistical technique to handle missing data that takes advantage of the flexi-
bility in modern computing. With it, each missing value is replaced by two or more imputed values in
order to represent the uncertainty about which value to impute (Rubin, 2004). According to the method for
‘repeated imputation’ inference, each of the simulated complete data sets is analysed by standard methods,
and the results are combined to produce estimates and confidence intervals that incorporate missing-data
uncertainty. Multiple imputation methods for related censoring problems regarding HIV data have been
developed by Mun˜oz et al. (1989) and Taylor et al. (1990). Dorey et al. (1993) applied multiple imputa-
tion to interval-censored data corresponding to threshold-crossing time in some trials. Threshold-crossing
times, somehow similar to viral load rebound, are common in medicine when patients move to a new risk
category after crossing a threshold on some prognostic variable and because patient’s examinations occur
only periodically, the exact time of crossing the threshold is only known to fall within a specified interval.
The article is organized as follows: in Section 2, we present the relevant notation and preliminaries used
throughout the paper. Following, in Section 3, we present our multiple imputation-based approach to fit
a mixed effects Cox model in the presence of interval-censored data. In Section 4, the methodology is
applied to the ATI data set, followed by the section dedicated to the study of the properties of the fixed
parameter estimators under different settings via a simulation study (Section 5). Finally, the main findings
of this work are summarized in Section 6 and, so far, unresolved topics are discussed. Information on the
implementation of the parameter estimation in R is presented in Appendix A and more details on the main
features of each study in ATI data set are given in Appendix B.
2 Notation and preliminaries
Let T be the time until the event of interest, ε, which in the ATI studies corresponds to viral rebound. T
is a non-negative random variable whose distribution function at time t, F (t) = P(T ≤ t), corresponds
to the cumulative probability of reaching viral rebound before time t. The hazard function defined by
λ(t) = lim∆t→0 1∆tP(t ≤ T < t + ∆t|T ≥ t), represents the instantaneous risk of viral rebounding and
it is the function on which the model we propose will be based on.
The observable data, based on a sample of n patients, consists, for the ith individual (i = 1, . . . , n),
of the random intervals (Li, Ri] during which the viral rebound occurred and the vector of covariates
xi = (xi1, . . . ,xir)
′, including the study label, gender, and pre-cART viral load. Interval-censored data
include right-censored times as a particular case with Ri = ∞, which in our data base corresponds to
patients whose viral load has not rebounded by the end of the study.
To obtain a non-parametric estimation of the survival function, S(t) = 1 − F (t), under interval cen-
soring, one of the most popular methods is Turnbull’s estimator (Turnbull, 1976). For this purpose, we
define the so-called Turnbull intervals, denoted by I = {(q1, p1], (q2, p2], . . . , (qm, pm]}, where I are
those intervals where all the mass of any non-parametric maximum likelihood estimator (NPMLE) will
be concentrated. To obtain these intervals, let L = {Li, 1 ≤ i ≤ n} and R = {Ri, 1 ≤ i ≤ n} be the
set of left and right endpoints respectively. We need to derive all the distinct intervals (qj , pj ] such that
qj ∈ L, pj ∈ R, and that there is no other left or right endpoint between qj and pj . The NPMLE for
the survival function decreases inside the set I and is constant outside of them. Specifically, denoting by
wj = P(qj < T ≤ pj) = S(qj)− S(pj) the weight of the jth Turnbull’s interval, the NPMLE for S(t) is
given by
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Sˆn(t) =
 1, if t ≤ q11− (wˆ1 + · · ·+ wˆj), if pj ≤ t ≤ qj+1, 1 ≤ j ≤ m− 1
0, if t ≥ pm
(1)
and is not specified within (qj , pj ], for 1 ≤ j ≤ m. Observe that Turnbull’s estimate of the survival
function has a special shape with horizontal stretches in non-Turnbull’s intervals and rectangular boxes
indicating areas of equal likelihood in Turnbull’s intervals.
Let λ(t|x) be the hazard function at time t for an individual with risk vector x. The basic model (Cox,
1972) is given by
λ(t|x) = λ0(t) exp(β′x) = λ0(t) exp
( s∑
k=1
βkxk
)
(2)
where λ0(t) is an arbitrary baseline hazard function and β = (β1, . . . , βs)′ is a parameter vector. Once
the model (2) has been established and assuming that the primary interest lies in the role played by the
fixed effects, the estimate of β must be addressed allowing that λ0(t) is arbitrary. Given that the baseline
function λ0(t) is not specified, to study the influence of the covariates in the survival times, a modification
of the classical theory of maximum likelihood is needed. With this goal Cox proposed the partial likelihood
function,
LP (β) =
k∏
j=1
exp{β′x(j)}∑
l∈R(t(j)) exp{β
′x(j)}
, (3)
where R(t(j)) is the risk set at time t(j) and t(1) < t(2) < · · · < t(k) are the k distinct failure times.
LP (β) is based on that part of the data that does not carry information about λ0(t). The partial likelihood
function is especially useful when it is much more simple than the complete likelihood function and it is
a good remedy when the general method of maximum likelihood is not adequate due to the presence of
many nuisance parameters (Go´mez & Cadarso-Sua´rez, 2017).
The Cox proportional hazards model, as described in (2), can be enhanced through the incorporation
of random effect terms to account for within-cluster homogeneity in outcomes. This model, called mixed
effects Cox model, was developed by Therneau & Grambsch (2000) and implemented for right-censored
data. The hazard function of a mixed effects Cox model for an individual i is given by
λi(t; X,Z) = λ0(t) exp(Xiβ + Zib) with b ∼ N(0,Σ(θ)), (4)
where Xi and Zi are the ith rows of the design matrices corresponding to the fixed and random effects, and
β and b are the vectors of the fixed and random effects coefficients, respectively. In addition, as above, λ0
is the unspecified baseline hazard function and the distribution of the random effects is assumed to follow
a Gaussian distribution with mean zero and covariance matrix
∑
, which in turn depends on a vector of
parameters θ.
The partial likelihood function corresponding to the mixed effects Cox model is similar to that of the
partial likelihood of the standard Cox model given in (3) and the expression of its logarithm for any fixed
values of β and b, is
LPL(β, b) = log{PL(β,b)} =
n∑
i=1
∫ ∞
0
[
Yi(t)ηi − log
{∑
j
Yj(t) exp(ηj)
}]
(5)
where ηi = Xiβ + Zib is the linear score for subject i and Yi(t) is an indicator variable that takes value
1, if individual i is at risk at time t and 0 otherwise; for further details, see Therneau (2018b).
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A straightforward adaptation of the partial likelihood function (5) to allow for the presence of interval-
censored data is not possible, because with such data, it is not feasible to identify the exact ranking of the
failure times and, consequently, the indicator variables Yi(t) cannot be determined for all t. Our proposal
to overcome that problem is to use multiple imputation to replace the interval-censored survival times by
exact and right-censored imputed values. The details are presented in the next section.
3 Parameter estimation in the mixed effects Cox model
The basic idea of our proposal consists of replacing the censoring intervals (L, R] that contain the unknown
survival times by imputed values based on a truncated Weibull distribution. The mixed effects Cox model
in (4) can then be fitted to the imputed exact and right-censored data. These steps will be repeated several
times in order to account for the uncertainty of the imputation step, which is ignored in the case of single
imputation. Our proposal can be summarized by the following three steps.
Step 1: Imputation of interval-censored survival times.
Censoring intervals are replaced by imputed times following two steps. First, an accelerated failure
time model is fitted to the whole data set, considering the covariates of interest, and the maximum
likelihood estimators of the corresponding parameters are derived. Second, for each individual’s cen-
soring interval, its corresponding truncated Weibull distribution is obtained, and a random value is
generated from that distribution. In the case of right-censored observations, no imputation is per-
formed. Hence, the resulting data set consists of uncensored (imputed) and right-censored survival
times.
Step 2: Fit of the mixed effects Cox model and analysis.
The mixed effects Cox model (4) described in the previous section is fitted with the data resulting
from Step 1 and the parameter estimates of interest are obtained.
Step 3: Pooling the results.
Given a pre-specified integer M , Steps 1 and 2 are repeated M times. Following, the parameters of
interest are estimated as the average values of the estimates obtained in each of the M repetitions of
Step 2.
Below we explain in more detail each of these steps.
3.1 Imputation of interval-censored survival times
The first step of our proposal consists of replacing the censoring intervals (L, R] by imputed values based
on a truncated Weibull distribution, where the truncation is induced by the respective intervals of the indivi-
duals. The motivation to use the Weibull distribution is twofold: on one hand, it is a common parametric
model for survival data due the simplicity of the survival function and the flexibility of the hazard func-
tion, which is either constant, monotonically increasing or monotonically decreasing. On the other hand, it
shares the assumption of proportional hazards with the Cox model. For that reason, given the Cox model
in (2) and assuming that the baseline hazard function follows a Weibull distribution with cumulative dis-
tribution function G(t) = 1− exp(−λtα), survival times can be generated using the following expression
(Bender et al., 2005):
T =
(− log(U)
λ exp(β′x)
)1/α
, (6)
where U follows a uniform distribution on the interval from 0 to 1.
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An estimation of β, λ, and α in (6) are obtained after fitting the following accelerated failure time model
–equivalent to the Cox model under the Weibull assumption–:
Y = log T = µ+ γ′X + σW,
where W follows the extreme value distribution. Standard software is used to obtain maximum likelihood
estimators of µ, γ and σ and, from these, maximum likelihood estimators of the parameters in (6) are
obtained by means of the following transformations:
λˆ = exp(−µˆ/σˆ), αˆ = 1/σˆ, βˆ = −γˆ/σˆ.
For each individual’s censoring interval an uncensored imputed survival time is randomly generated
using its corresponding truncated Weibull distribution with parameters λˆ, αˆ and βˆ. No imputation is
needed in the case of right-censored observations.
Regarding truncated distributions and according to Nadarajah & Kotz (2006), letX be a random variable
representing the truncated version of some distribution function G(·), over the interval (Li, Ri] of each
individual with 0 < Li < Ri < ∞. It is straightforward to check that the distribution function of X is
given by
FXi(x) =
G(max(min(x,Ri), Li)|ϑˆ)−G(Li|ϑˆ)
G(Ri|ϑˆ)−G(Li|ϑˆ)
,
and its corresponding inverse by
F−1Xi (p) = G
−1(G(Li|ϑˆ) + p(G(Ri|ϑˆ)−G(Li|ϑˆ))).
Hence, to obtain a random value of X , for every censoring interval (Li, Ri], a random uniform number ui
is generated and an imputed value xi = F−1X (ui) is derived.
Given an original sample of n individuals with n − r interval-censored and r right-censored survival
times, step 1 yields a sample of size n with n − r imputed uncensored and the r right-censored survival
times. In the next step, a mixed effects Cox model can be fitted to this sample as we explain below.
3.2 Fit of the mixed effects Cox model
In this step, the mixed effects Cox model (4) explained in Section 2 is fitted using the previously imputed
values. The objective here is to estimate the vector of fixed effects regression parameters β and the vector
of parameters θ for the covariance matrix Σ of the random effects. In what follows, we sketch the main
ideas of Therneau’s method (Therneau, 2018a).
The MLE for β and θ is based on an integrated penalized partial likelihood (IPL)
IPL(β,θ) =
1
(2pi)q/2|Σ(θ)|1/2
∫
PL(β, b) exp{−b′Σ−1(θ)b/2} db (7)
where b is the vector of random effects coefficients, as presented in (4) and q corresponds to the number of
random effects. When the variance of the random effect is zero, this collapses to the ordinary Cox partial
likelihood.
Since expression (7) is not a tractable integral and in order to perform computations under this likeli-
hood, we rewrite the logarithm of the integrand of equation (7), that is, LPPL(β, b,θ) = LPL(β, b) −
(1/2)b′Σ−1(θ)b, as a second-order Taylor series about (βˆ, bˆ) as follows
LPPL(β, b,θ) ≈ LPPL(βˆ(θ), bˆ(θ))− (1/2)(β − βˆ, b− bˆ(θ))′H(β − βˆ, b− bˆ(θ))
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where the Hessian H is evaluated at (βˆ(θ), bˆ(θ)). When θ and hence Σ(θ) are fixed, the relevant values
of β and b that maximize LPPL(β, b,θ) are easily obtained using essentially the same methods as an
ordinary Cox model.
As we are only interested in the values at βˆ, the last term collapses to (0, b − bˆ)′H(0, b − bˆ) =
(b − bˆ)′Hbb(b − bˆ), where Hbb is the portion of the Hessian corresponding to the random effects. When
we replace the body of the integral in (7) with this approximation, then the result is an integral that can be
solved in closed form. For further details see Therneau (2018a).
Basically, in this second step by fitting the mixed effects Cox model presented in (4), we obtain an
estimation of the parameter vectors β and b as well as of the corresponding covariance matrices.
3.3 Pooling the results
We need to repeat the previous steps (Steps 1 and 2) M times, where M is a pre-specified integer. The M
complete-data analyses corresponding to theM imputations under the mixed effects Cox model result inM
repeated complete-data statistics, and these are combined to form one repeated-imputation inference that
appropriately adjusts for interval-censored data under the model used to create the repeated imputations.
The estimated parameter vectors and their corresponding covariance matrices obtained in the M repeti-
tions of steps 1 and 2 are denoted by βˆm, bˆm, Σˆβm, Σˆ(θ)m, m = 1, . . . ,M .
Given a particular fixed effects parameter βi, the repeated-imputation estimate βˆi,MI is the average over
the M estimates of this parameter, that is, βˆi,MI =
(∑M
m=1 βˆi,m
)
/M . In addition, multiple imputation
also provides a simple formula to estimate the variance of βˆi,MI (Rubin, 2004), namely,
V̂ar(βˆi,MI) = Ui,MI +
(
1 +
1
M
)
Bi,MI,
whereUi,MI =
(∑M
m=1 V̂ar(βˆi,m)
)
/M is the within-imputation variance andBMI is the between-imputation
variance given by Bi,MI =
(∑M
m=1(βˆi,m − βˆi,MI)2
)
/(M − 1) . The BMI term is inflated by a factor 1/M
to take into account the finite number of imputations.
The same procedure is applied for the estimation of the random effects as well as for the elements of
the covariance matrices.
3.4 Software issues
We have accomplished the imputation process in R using the truncdist contributed package (Novomestky
& Nadarajah, 2016). This package includes the function rtrunc to impute the values per subjects. This
function generates n random deviates that are drawn from the specified truncated distribution.
To fit the mixed effects Cox model, we used the R package called coxme (Therneau, 2018b). The
central computational strategy implemented in this package is an outer and an inner loop. The outer loop
searches over the parameters θ of the variance matrix for a maximum of the IPL (7) and does it in 3 steps.
For each trial value of θ in this search, the first step is to calculate Σ(θ) and Σ−1(θ). The second step
is to solve the penalized Cox model LPL(β, b) − (1/2)b′Σ−1b to get the solution vector (βˆ, bˆ). The
iterative Newton-Raphson solution to this problem is the inner loop. The third step is to use the Laplace
approximation to compute the log IPL, using the results of step 2. The implemented R code to follow the
algorithm is presented in Appendix A.
4 Effect of gender and pre-cART VL on the time to HIV RNA viral re-
bound considering multiple random effects
The ATI data set (Leal et al., 2017) that motivated this study corresponds to a recompilation from 229 ATI
episodes belonging to 158 different patients. The main virologic outcome of interest in these studies is
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the time to viral rebound, defined as the time between treatment interruption and the first detectable serum
viral load (VL), which is measured as the number of HIV copies in a millilitre of blood. For the purpose
of statistical analyses, it is commonly log-transformed because of its right-skewed distribution.
Following, we present a description of some of the variables in the data set. Therein, we refer to the
eight studies by Study 1 to Study 8. More detailed information on the studies, including the inclusion
criteria and the interventions, is provided in Appendix B. In addition, we will refer to the last viral load
before the first initiation of cART by pre-cART VL.
4.1 Descriptive analysis of the ATI dataset
Table 1 presents the gender distribution and a numeric description of the log pre-cART VL separately for
each of the eight studies as well as overall. Therein, NATI denotes the number of ATI periods per study and
N the number of patients. As shown, 158 patients were involved in the 8 studies with a total of 229 ATI
periods. Fifty nine patients were exposed to an immunomodulating intervention of some kind and 61% of
the patients were men. Notice that in the case of both Study 6 and 7, we did not obtain the information on
the gender of 17 patients. Concerning the pre-cART VL of the patients, the overall median of the log base
10-transformed pre-cART VL was 4.37 with similar values in all but one study (Study 4), within which the
median log pre-cART VL was clearly lower (3.19). The reason for this resides in the inclusion criteria for
Study 4 as explained in Appendix B.
Table 1 Description of the eight studies in ATI data set.
Gender Log pre-cART VL
Study nATI n
Male
(Fem) Missing
Mean
(SD)
Median
(IQR)
Min
Max Missing
Overall 229 158a 96
(28)
34 4.37
(0.7)
4.31
(3.98 - 4.86)
2.33
6.00
3
Study 1 (Garcı´a et al., 2005) 32 16 14
(2)
0 4.14
(0.64)
4.16
(3.88 - 4.57)
3.10
5.17
0
Study 2 (Garcı´a et al., 2013) 70 35 27
(8)
0 4.78
(0.56)
4.69
(4.38 - 5.16)
3.20
5.74
0
Study 3 (ClinicalTrials.gov
Identifier: NCT 02767193)
18 18 18
(0)
0 4.12
(0.57)
4.19
(3.95 - 4.48)
2.33
4.76
0
Study 4 (Garcı´a et al., 2004) 11 11 5
(6)
0 3.21
(0.37)
3.19
(3.08 - 3.40)
2.61
3.80
0
Study 5 (Garcı´a et al., 2003) 20 20 15
(5)
0 4.50
(0.49)
4.48
(4.11 - 4.89)
3.80
5.40
0
Study 6 (Mothe et al., 2015) 28 28 10
(1)
17 4.46
(0.77)
4.28
(3.96 - 4.87)
3.33
6.00
3
Study 7 (Fagard et al., 2003) 33 33 11
(5)
17 4.43
(0.52)
4.45
(4.08 - 4.70)
2.84
6.00
0
Study 8 (Garcı´a et al., 1999, 2001) 17 10 7
(3)
0 4.59
(0.56)
4.40
(4.31 - 4.89)
3.89
5.70
0
aThe sum of the column is not equal to 158 because of patients belonging to more than one study.
Concerning the time until viral rebound, all but one of the 158 patients suffered a viral rebound during
the respective follow-up times of the ATI studies and since VL was determined weekly, all these times
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were interval-censored. The exception corresponds to a right-censored observation of a patient in Study 5,
whose viral load was below 20 copies/mL after four weeks when it was measured the last time. A graphical
representation of all censoring intervals is shown in Figure 2, wherein, it can be observed that all interval
lengths are multipliers of one week. This is due to the fact that the medical follow-up visits in all included
studies were programmed with exact multiples of seven days following a strict protocol.
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Figure 2 Lengths of the ordered interval-censored times (weeks) until viral rebound of the 229 ATI
episodes. The average length of the censoring intervals is 2.6 weeks.
Additionally, in Figure 3, we provide the Turnbull estimates of the distribution functions of the time
until viral rebound, obtained from Formula (1) by 1 − Sn(t). Therein, we can observe that the estimated
probabilities of a viral rebound within the first two and four weeks are close to 0.6 and 0.9, respectively.
Moreover, the separate Turnbull estimates of F (t) in Studies 1 through 8 reflect a notable heterogeneity
among the ATI studies: for example, the estimated probabilities of a viral rebound within the first two
weeks vary from less than 0.2 (Study 4) to more than 0.8 (Study 1).
c© 20zz WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
Biometrical Journal xx (20zz) yy 11
Figure 3 Non-parametric estimation of the distribution function of the time until viral rebound. The
first graph (upper left corner) shows the estimation based on the pooled sample, the remaining graphs
correspond to Studies 1 through 8.
4.2 Fit of the mixed effects Cox model
For the purpose of studying the possible effect of gender and log pre-cART VL on the time until viral
rebound taking into account the within-subject and within-study correlation, we fitted the mixed effects
model presented in (4):
λi(t; X,Z) = λ0(t) exp(Xiβ + Zib) with b ∼ N(0,Σ), (8)
where X ∈ IR229×2 is the design matrix of the fixed effects Gender and log pre-cART VL and β ∈ IR2 is
the fixed effects parameter vector. In the case of the log pre-cART VL, we decided to subtract 4, which is
equivalent to a VL of 10000 HIV copies in a millilitre of blood and close to the overall median (4.31), since
the value 0 was outside the range of the variable (Table 1). Concerning the random effects, we considered a
random intercept per patient as well as correlated random intercept and slope for log pre-cART VL within
each study. Hence, b = (b′1, b
′
2, b
′
3)
′ ∈ IR158+8+8 and Z ∈ IR229×174. In addition, the covariance
matrix of b is given by
Σ =
σ2b1 0 00 σ2b2 σb2,b3
0 σb2,b3 σ
2
b3
 .
Notice that the inclusion of a random intercept per study implies study-specific baseline hazard functions
λ0,1(t), . . . , λ0,8(t).
For the model fit, we used the 3-step algorithm proposed in Section 3. In the first step of the algorithm,
we replaced the interval-censored times until viral rebound by imputed times obtained randomly from the
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truncated Weibull distribution, and in Step 2, Model (4) was fitted. Steps 1 and 2 were repeated M = 15
times providing the parameter estimates corresponding to the fixed effects presented in Table 2.
Table 2 Estimation of the fixed effects parameters and the standard deviation of the random effects of
Model (4) using the three-step imputation method.
βˆ se(βˆ) ĤR 95%CI
Gender (Female vs Male) 0.50 0.26 1.65 [0.99, 2.74]
Log pre-cART VL 0.60 0.23 1.83 [1.16, 2.86]
Random effects σˆb1 σˆb2 σˆb3 Ĉorrb2,b3
0.35 0.34 0.34 -0.47
According to the results obtained, the instantaneous risk of viral rebound among female patients is 1.65
times larger than the instantaneous risk among male patients with the same pre-cART VL. However, since
the standard error is relatively large, the corresponding 95% confidence interval of the hazard ratio does
include 1 and, hence, we actually cannot claim that women are at larger risk for viral rebound than men
among the population of HIV-infected persons at a confidence level of 0.95. Concerning pre-cART VL,
the results obtained are clear: the larger the pre-cART VL, the larger the risk of suffering a viral rebound.
The adjusted hazard ratio of 1.83 implies that a unit increase of the log pre-cART VL, that is, a 10-fold
increase of the VL, increases the instantaneous risk of a viral rebound by factor 1.83.
Regarding the random effects, the estimated standard deviation of the random intercept per subject, σˆb1
can be interpreted as the unexplained variation between individuals after controlling for the explanatory
variables in the model. The value of the estimated standard deviation of the random intercept per study,
σˆb2 , reflects the heterogeneity among the eight studies with respect to the inclusion criteria. The standard
deviation σˆb3 quantifies the variability of the slopes of pre-cART VL among the eight studies. The study-
specific hazard ratios associated to pre-cART VL varies from 1.28 (Study 2) to 2.49 (Study 8; values not
shown). Moreover, the negative value of the estimated correlation (-0.47) between random intercept and
random slope of pre-cART VL, implies that the smaller the baseline hazard function per study, the larger
the effect of the pre-cART VL.
5 Simulation study
The objective of the following simulation study was to explore the properties of the estimation method
presented in Section 3 in terms of bias and mean squared error of the fixed effects estimator βˆ in a setting
very similar to the one of the data set at hand.
5.1 Simulation settings and data generation
Data sets were generated based on Model (8) under a total of 36 different scenarios shown in Table 3.
Common to all scenarios, which were motivated by the data set presented in Section 4, were the distri-
butions of the fixed effects variables X1 (Binomial(1, 0.23)) and X2 (N(0, 0.7)) as well as the parameter
values β1 = 0.5 and β2 = 0.6. Regarding the random effects, the variable Study was generated from a
multinomial distribution with equal probabilities for each of the eight studies, i.e., p = 1/8. In the case of
Studies 1, 2, and 8, we duplicated the ATI episodes per patient, in order to reproduce the scenario of the
real data set. The values of the random effects b1, b2, and b3 were generated from a multivariate normal
distribution with mean 0 and
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Table 3 Settings of the simulation study
Sample size n ∈ {100, 200, 300}
Assessment probability p ∈ {0.2, 0.33, 0.5}
Number of imputations M = 15
Distribution of T Weibull, Gompertz
Percentage of right-censored observations 0 and 10
Distribution of X1 Bin(1, 0.23)
Distribution of X2 N(0, 0.7)
(β1, β2)
′ (0.5, 0.6)′
Distribution of b1, b2, b3 MVN(0,Σ) (see (9))
Σ =
0.352 0 00 0.352 −0.47 · 0.35 · 0.35
0 −0.47 · 0.35 · 0.35 0.352
 . (9)
To generate survival times from the mixed effects proportional hazards model in (8), we used the inverse
probability method described by Bender et al. (2005). According to the authors, a random survival time
from Model (8) can be generated using the following equation:
T = Λ−10
(
− log(U)
exp (Xβ +Zb)
)
,
where U follows a uniform distribution in the interval (0, 1) and Λ0 is the cumulative baseline hazard func-
tion. Survival times can be generated assuming the conditional distribution of T givenX and Z follows a
Weibull or Gompertz distribution since both share the assumption of proportional hazards (Bender et al.,
2005).
In the case of the Weibull distribution with shape and scale parameters κ > 0 and ρ > 0, the baseline
hazard function is λ0 = κρ(ρt)κ−1. Hence, Λ0(t) = (ρt)κ, and following the inverse probability method,
a realization of T is obtained by computing
t =
{− log(u) · exp (−Xβ −Zb)}1/κ
ρ
,
where u is a realization of U .
Regarding the Gompertz distribution with shape and scale parameters α ∈ (−∞,∞) and ρ > 0, the
baseline hazard function is λ0 = ρ exp{αt}. Hence, Λ0(t) = (ρ/α) · (exp (αt) − 1), and following the
inverse probability method, a realization of T is obtained by computing
t =
1
α
· log (1− α log(u)
ρ exp (−Xβ −Zb)
)
.
Notice that in the case of α < 0 there is a point mass at infinity since the argument of the log function
could then be negative. However, this possibility was ruled out in the simulation study as α = 1.5 was
used to generate the data.
Given all survival times Ti, i = 1, . . . , n, per data set, the censoring intervals (Li, Ri] were generated
assuming noninformative censoring and following the procedure described in Go´mez et al. (2009). All
integers from 1 through 12, the maximum upper limit of the censoring intervals in our data set (Figure 2)
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were considered possible assessment times using three different assessment probabilities for each of the
12 values: p ∈ {0.2, 0.33, 0.5}. That is, the assessment times were generated according to a Bernoulli
distribution with parameter p and for each survival time Ti generated, the interval (Li, Ri] was obtained
as the smallest interval of assessment times among all those including Ti.
In addition to the underlying distribution and the assessment probabilities, the different scenarios were
determined by the sample size per data set (n ∈ {100, 200, 300}) and the percentage of right-censored
observations (none and 10%, respectively). The number of imputations was kept the same for all settings
(M = 15).
5.2 Evaluation criteria
Given any of the 36 simulation settings, we generated D = 1000 data sets, for each of which β1 and β2
were estimated by means of the method presented in Section 3. Thus, we obtained βˆd = (βˆ1,d, βˆ2,d)
′
for d = 1, . . . , D. Based on these estimations and given the true parameter vector β0 = (0.5, 0.6)′, we
calculated the mean, variance, bias, and mean squared error (MSE) of βˆ1, and βˆ2 as follows:
¯ˆ
βi =
1
D
D∑
d=1
βˆi,d, i = 1, 2,
V̂ar(βˆi) =
1
D − 1
D∑
d=1
(βˆi,d − ¯ˆβi)2, i = 1, 2, (10)
B̂ias(βˆi) =
¯ˆ
βi − β0,i, i = 1, 2,
M̂SE(βˆi) = V̂ar(βˆi) + B̂ias(βˆi)2, i = 1, 2.
The bias is a measure for the accuracy of the estimators, whereas the MSE can be used as a measure for
the precision.
Concerning the estimation of the variance, Var(βˆi,d) could also be estimated within each of the D
runs and their mean could serve as well as an estimator of Var(βˆi), i = 1, 2. However, Formula (10) is
generally more appropriate, since the mean of the D variance estimates usually underestimates the true
variance Var(βˆi).
The whole simulation process was programmed in R (R Core Team, 2018) using the function multimp
(see Appendix A) and is included in the Supporting Information.
5.3 Simulation results
The results of the simulations in terms of bias and MSE are shown in Tables 4 (no right-censored data)
and 5 (10% of right-censored observations). In general, for the settings under study, it can be observed
that our proposed method captures the real parameters in a proper way. Irrespective of the conditional
distribution of T or the percentage of right-censored observations, the estimated bias of both βˆ1 and βˆ2 can
be considered small.
Concerning the conditional distribution of the survival times, hardly any difference is observed between
the Weibull and the Gompertz distribution with respect to the bias even though the former is always used for
the imputation step of our method. Contrary to that, the MSE is generally larger in case of the Gompertz
distribution indicating a somewhat smaller precision in that case. Only slight differences are observed
comparing the settings without and with 10% of right-censored data. In the case of no right-censored
observations, the bias is generally a bit lower, whereas the MSE is slightly bigger in most cases.
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Table 4 Fixed parameters estimators without right-censored observations and 15 imputations (β1 =
0.5, β2 = 0.6)
Weibull Gompertz
Bias MSE Bias MSE
n = 100
Assessment probability: p = 0.2
βˆ1 0.060 0.246 0.045 0.293
βˆ2 -0.001 0.078 -0.022 0.089
Assessment probability: p = 0.33
βˆ1 0.035 0.132 -0.007 0.135
βˆ2 0.005 0.054 -0.030 0.064
Assessment probability: p = 0.5
βˆ1 0.001 0.090 -0.004 0.092
βˆ2 -0.009 0.051 -0.021 0.049
n = 200
Assessment probability: p = 0.2
βˆ1 -0.023 0.073 -0.028 0.092
βˆ2 -0.029 0.039 -0.045 0.042
Assessment probability: p = 0.33
βˆ1 -0.034 0.049 -0.035 0.061
βˆ2 -0.036 0.032 -0.044 0.038
Assessment probability: p = 0.5
βˆ1 -0.023 0.038 -0.032 0.041
βˆ2 -0.032 0.030 -0.054 0.031
n = 300
Assessment probability: p = 0.2
βˆ1 -0.038 0.046 -0.046 0.054
βˆ2 -0.045 0.028 -0.064 0.036
Assessment probability: p = 0.33
βˆ1 -0.040 0.034 -0.051 0.039
βˆ2 -0.045 0.027 -0.043 0.027
Assessment probability: p = 0.5
βˆ1 -0.040 0.027 -0.032 0.029
βˆ2 -0.043 0.024 -0.052 0.027
The sample size does have the expected impact on the precision of βˆ1 and βˆ2: the MSE decreases as n
increases no matter the width of the intervals or the conditional distribution of the survival times. In terms
of bias, generally, no big differences are observed between the different sample sizes. However, with a
sample size of n = 100, the bias seems to depend on the assessment probability: the larger the assessment
probability and, hence, the smaller the censoring intervals, the more accurate the estimator. This tendency
is, generally, not observed for n = 200 and n = 300. Moreover, the bias, even though generally small, is
almost always negative in the case of n = 200 and n = 300 indicating, hence, a slight underestimation of
both parameters. By contrast, with a sample size of 100, the bias is most often positive.
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Table 5 Fixed parameters estimators considering 10% right-censored observations and 15 imputations
(β1 = 0.5, β2 = 0.6)
Weibull Gompertz
Bias MSE Bias MSE
n = 100
Assessment probability: p = 0.2
βˆ1 0.088 0.315 0.071 0.342
βˆ2 0.027 0.090 -0.015 0.091
Assessment probability: p = 0.33
βˆ1 0.019 0.140 0.011 0.143
βˆ2 0.019 0.061 -0.018 0.062
Assessment probability: p = 0.5
βˆ1 0.013 0.097 0.001 0.098
βˆ2 0.007 0.055 -0.005 0.053
n = 200
Assessment probability: p = 0.2
βˆ1 0.001 0.085 -0.022 0.091
βˆ2 -0.024 0.045 -0.030 0.047
Assessment probability: p = 0.33
βˆ1 -0.017 0.052 -0.010 0.065
βˆ2 -0.019 0.036 -0.028 0.035
Assessment probability: p = 0.5
βˆ1 -0.017 0.043 -0.015 0.046
βˆ2 -0.023 0.030 -0.033 0.031
n = 300
Assessment probability: p = 0.2
βˆ1 -0.030 0.049 -0.037 0.057
βˆ2 -0.033 0.033 -0.054 0.036
Assessment probability: p = 0.33
βˆ1 -0.034 0.036 -0.030 0.037
βˆ2 -0.036 0.027 -0.041 0.029
Assessment probability: p = 0.5
βˆ1 -0.027 0.028 -0.013 0.029
βˆ2 -0.023 0.025 -0.031 0.026
6 Discussion
Our collaboration as data scientists with clinicians and virologists from Hospital Clı´nic of Barcelona, IRB
Barcelona, and University of Barcelona led to the analysis of the eight different Analytical Treatment
Interruption studies in chronic HIV-positive combination Antiretroviral Therapy (cART)-suppressed indi-
viduals. The main clinical question to be studied was whether gender and pre-cART VL were risk factors
on the time until viral rebound in HIV-infected patients with previously undetectable viral load, taking into
account the heterogeneity between the different studies and the fact that different patients had different
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number of ATI episodes. The first challenge we encountered was that the times until viral rebound were
interval-censored. Other difficulties were that the studies had different inclusion criteria (for example, with
respect to pre-cART VL values), and that some individuals participated in more than one study or were
exposed to more than one ATI episode.
For these reasons, the analysis of this data set with the mixed effects Cox model seemed to be the
natural choice. However, to the best of our knowledge, this model had not been studied with interval-
censored data previously. Hence, our proposal is a first step to close the gap between the mixed effects Cox
model (Therneau & Grambsch, 2000) and the Cox model with interval-censored data (Finkelstein, 1986).
The method proposed is based on multiple imputations in order to replace the censoring intervals by
imputed values to simplify the data structure to uncensored and possibly right-censored survival times.
For this step, we propose to generate random survival times from a truncated Weibull distribution. As an
alternative to multiple imputation, single imputation methods imputation could have been applied, such
as midpoint imputation replacing the censoring interval (Li, Ri] by its midpoint (Li + Ri)/2. However,
midpoint imputation is only reasonable when the time period between consecutive visits (or measurements)
is short leading to approximately unbiased estimations. But even in this case, the standard error of the
estimator would be underestimated since single imputation methods ignore the imputation uncertainty
(Kim, 2003) and do not take into account the variability of the censoring interval. In contrast, multiple
imputation does not attempt to estimate each missing value through simulated values but rather to represent
a random sample of the missing values. This process results in valid statistical inferences that properly
reflect the uncertainty due to missing data (Yuan, 2010).
According to the results of the simulation study presented in Section 5, the estimation method proposed
has desirable properties in terms of accuracy (small bias) and precision (low MSE) of the estimators of the
fixed effects parameters. A relatively large MSE was only observed in the case of the smallest sample size
(n = 100) and smallest assessment probabilities (p = 0.2) considered (see Tables 4 and 5). We have to
admit, however, that the simulation study did only comprise 36 different scenarios determined by sample
size, assessment probability, condition distribution of T given X and Z, and the percentage of right-
censored observations. Further simulation studies would be desirable in order to explore the properties of
our estimation method under additional settings or with mixed effects Cox models with a different number
of fixed and random effects.
An apparent limitation of our estimation methods seems to be the fact that the imputation step is based
exclusively on the (truncated) Weibull distribution. However, the Weibull distribution is a flexible distri-
bution in the sense that its hazard function can have different shapes (constant, monotonically increasing,
or monotonically decreasing). For this reason, its use must not necessarily be a limitation even though the
underlying survival time distribution may be a different distribution. Actually, the simulation results in the
case of the Gompertz distribution of T (small bias and low MSE) seem to confirm this supposition.
An important aspect of model fitting that has been beyond the scope of the present work is the compari-
son of nested mixed effect Cox models in the presence of interval-censored data. Nested mixed effects
Cox models with right-censored data can be compared by means of the values of the log partial likelihood
function after integrating out the random effects (Therneau, 2018b), whose difference multiplied by minus
2 follows a chi-squared distribution under the null hypothesis that the nested model does not improve
the model fit. In our case, for example, we could be interested in testing, whether the inclusion of the
different random effects actually improve the model fit. The application of the Likelihood Ratio Test
proposed by Therneau (2018b) with our estimation method, however, is not straightforward because of the
multiple imputations. One possible ad hoc solution to this question could be to compute, separately for
the models to be compared, the corresponding values of the integrated log partial likelihood for each of the
M model fits obtained with each imputation. Following, the mean difference over the M model fits could
be calculated and compared to the quantiles of the corresponding chi-squared distribution. Further studies
should address this topic in order to develop guidelines for researchers for how to compare nested mixed
effects Cox models with interval-censored data.
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Concerning the clinical results obtained, as could be expected, the higher the last viral load before the
first initiation of cART (pre-cART VL), the larger the instantaneous risk of a viral rebound. In our data
set, female patients were at larger instantaneous risk for viral rebound than male patients with the same
pre-cART VL, however, using a 95% confidence level, we cannot claim that this is also valid among the
population of HIV-infected patients. We did not study any further variables, but our R function multimp
could be easily adapted to the estimation of more than two fixed parameters. The same could be done to
consider more random effects.
We did also check whether the inclusion of the patient identifier and the (correlated) intercept and slope
of pre-cART VL among studies as a random effects in the Cox model modifies the results obtained from a
Cox model that ignored such random effects. To fit this model, we used the icenReg package (Anderson-
Bergman, 2017), which enables the parameter estimation in the Cox model in the presence of interval-
censored data. The differences observed were: βˆ1 = 0.51 versus βˆ1 = 0.50 in the case of variable Gender,
and βˆ2 = 0.36 versus βˆ2 = 0.60 in the case of pre-cART VL. That is, ignoring the random effects ATI
Study and patient identifier, the estimated hazard ratio associated with pre-cART VL would have been 1.43
and, hence, notably smaller than the estimated hazard ratio 1.83 reported in Section 4. These differences
highlight the importance to consider random effects when fitting a Cox model in the presence of interval-
censored data and a grouped data structure.
In Table 2, we also report the estimated standard deviations of the random effects. However, as Gleiss
et al. (2018) point out, the values presented lack the direct comparability with the contribution of fixed
effects. The authors are working on this issue addressing the explained variation in shared frailty models,
which are a particular case of the mixed effects model, namely when a random intercept per random effect
is considered.
Even though we have applied our method only to one data set, our method is valid for any data set
that presents both interval-censored survival times and a grouped data structure that could be treated as
a random effect in a regression model. Nonetheless, a fit of the mixed effects Cox model with interval-
censored data that did not require multiple imputations would be desirable. For this purpose, the expression
of the likelihood function of the Cox model with interval-censored data presented by Finkelstein (1986)
would need to be extended to consider random effects and tools of the area of optimization such as the
ones presented by Langohr & Go´mez (2005) could be useful to achieve this goal.
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A R code used to fit the mixed effects Cox model
multimp <- function(data, Tl, Tu, dist = "weibull", nimp, uncens,
var1, var2, rand1, rand2){
require(truncdist)
require(coxme)
require(actuar)
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aft <- survreg(Surv(t1, t2, cens, type="interval") ∼ var1 + var2, data)
lambda <- exp(-aft$coef[[1]]/aft$scale)
alpha <- 1/aft$scale
mat <- matrix(0, ncol = nimp, nrow = nrow(data))
colnames(mat) <- as.vector(paste("M", 1:nimp, sep = ""))
for(i in 1:nrow(data)){
mat[i,] <- with(data,
rtrunc(nimp, spec = dist,a = Tl[i], b = Tu[i],
shape = alpha,
scale = (lambda * exp(-(aft$coef[[2]] *
data$var1[i]/sca
+ aft$coef[[3]] *
data$var2[i]/sca)))ˆ(-1/alpha)))
}
mat[data$Tu == Inf, ] <- rep(data$Tl[data$Tu == Inf], nimp)
dat <- data.frame(data, mat)
S <- vector("list", nimp)
mfit <- vector("list", nimp)
beta1 <- rep(0, nimp)
varbeta1 <- rep(0, nimp)
beta2 <- rep(0, nimp)
varbeta2 <- rep(0, nimp)
std1 <- rep(0, nimp)
std2 <- rep(0, nimp)
std3 <- rep(0, nimp)
corr1 <- rep(0, nimp)
for(i in 1:nimp){
S[[i]] <- with(dat, Surv(dat[,(ncol(dat) - nimp + i)],
uncens))
mfit[[i]] <- coxme(S[[i]] ˜ var1 + var2 + (1|rand1)
+ (1 + var2 | rand2), dat)
beta1[i] <- as.numeric(fixef(mfit[[i]])[1])
varbeta1[i] <- as.numeric(vcov(mfit[[i]])[1])
beta2[i] <- as.numeric(fixef(mfit[[i]])[2])
varbeta2[i] <- as.numeric(vcov(mfit[[i]])[4])
std1[i] <- sqrt(mfit[[i]]$vcoef[[1]])
std2[i] <- sqrt(mfit[[i]]$vcoef[[2]][1])
std3[i] <- sqrt(mfit[[i]]$vcoef[[2]][4])
corr1[i] <- mfit[[i]]$vcoef[[2]][2]
}
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b1 <- round(mean(beta1),3)
wi1 <- mean(varbeta1)
bi1 <- (sum((beta1-b1)ˆ2))/(nimp - 1)
varb1 <- wi1 + (1 + (1/nimp)) * bi1
sb1 <- round(sqrt(varb1), 4)
hr1 <- round(exp(b1), 2)
ci1 <- round(hr1 * exp(qnorm(c(0.025, 0.975)) * sb1), 2)
b2 <- round(mean(beta2), 3)
wi2 <- mean(varbeta2)
bi2 <- (sum((beta2 - b2)ˆ2))/(nimp - 1)
varb2 <- wi2 + (1 + (1/nimp)) * bi2
sb2 <- round(sqrt(varb2), 4)
hr2 <- round(exp(b2), 2)
ci2 <- round(hr2 * exp(qnorm(c(0.025, 0.975)) * sb2), 2)
sd1 <- round(mean(std1), 2)
sd2 <- round(mean(std2), 2)
sd3 <- round(mean(std3), 2)
cor <- round(mean(corr1), 2)
vars <- c(b1, sb1, hr1, ci1, b2, sb2, hr2, ci2, sd1, sd2, sd3, cor)
names(vars) <- c(’Coef’, ’se(coef)’, ’HR’, ’Lower 95%’, ’Upper 95%’,
’Coef’, ’se(coef)’, ’HR’, ’Lower 95%’, ’Upper 95%’,
’sd1’, ’sd2’, ’sd3’, ’Corr’)
return(vars)
}
B Additional information on the ATI data set
The eight ATI studies differ from each other with respect to the types of intervention defined by different
therapeutic vaccines or drug combinations during the combination Antiretroviral Therapy (cART) and the
inclusion criteria, which depended on the CD4 cell count, the plasma viral load (VL), previous years during
cART, or the stage of infection; see Table 6. In addition, the number of patients varied from one study to the
other as well as the geographical recruitment area. Following, some more detailed information is provided
on each study.
In Study 1 (Garcı´a et al., 2005), the first ATI episode was done to harvest autologous HIV virus to create
the therapeutic vaccine. The therapeutic vaccine was administered just before the second ATI. Patients are
coming from a previous study with non-advanced chronic HIV-1 infection.
Study 2 (Garcı´a et al., 2013) has a similar design as that of Study 1. In this study, there are 2 ATI
episodes, the first one is to harvest the autologous virus and the second is the post-vaccine stop.
Study 3 (https://clinicaltrials.gov/ct2/show/NCT02767193) corresponds to the on-
going new version of the dendritic cell-based vaccine trial. The first ATI episode was done, as in the previ-
ous studies, to harvest autologous HIV virus to create the therapeutic vaccine, which was administered just
before the second ATI. Patients in this trial had to be on stable cART for at least one year and the average
of all measurements of CD4 cells during the year before starting cART.
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Study 4 (Garcı´a et al., 2004) was carried out to evaluate the effect of mycophenolate mofetil (MMF)
on the immunologic control during the ATI. In particular, the first ATI episode was done to evaluate the
effect of MMF over the viral load dynamics. MMF is a well characterized drug widely used in renal
transplantation because of its ability to selectively inhibit lymphocyte division and it may inhibit HIV
replication. Patients were chronic HIV-1 infected persons at very early stages and were treated with cART
for 12 months.
Part of the objectives of Study 5 (Garcı´a et al., 2003) was to study the effect of concomitant hydroxyurea
treatment (HU), which was administered to a group of patients but not in the first ATI episode. The study
group were patients with chronic HIV infection from the Spanish EARTH-2 study. This study 5 was a de-
signed study to explore the effect of controlled and repeated interruptions over the immune response against
the virus. They were based on the ‘autovaccination’ theory, as explained in the introduction. The first ATI
episode does not have any specific ‘importance’, but the joint set of ATI episodes (which corresponds to
the studied intervention in this case).
Study 6 (Mothe et al., 2015) corresponds to patients participating in a randomized phase I HIV vaccine
trial with recombinant modified vaccinia Ankara-based and Gag-Pol-Nef polyprotein with or without a
drug to reactivate latent HIV in 3 centers. The only ATI episode of this study was done 8 weeks after the
last dose of MVA-B and the viral rebound dynamics were assessed during the first 12 weeks after cART
interruption. The ATI was done to evaluate the effect of the vaccine in the control of viral load during the
absence of cART. Participants were chronically HIV-infected individuals recruited at three HIV units in
Barcelona and Madrid (Spain).
In Study 7 (Fagard et al., 2003), cART was interrupted for 2 weeks, restarted for 8 weeks. After 4
such cycles, treatment was indefinitely suspended 40 weeks after study entry. The ATI rationale in this
study is to try to prove the ‘autovaccination hypothesis’, that is that reexposure to HIV during treatment
interruptions may stimulate the HIV-specific immune response and lead to low viremia after withdrawal of
cART.
Study 8 (Garcı´a et al., 1999, 2001) involved patients with chronic HIV-1 infection in very early stages
who started a twice daily three-drug regimen. cART was discontinued after one year of treatment and
effective virologic response. The ATI rationale in this study is the same as in the Study 5.
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Table 6 Inclusion criteria and treatment for the different studies of the ATI data set.
Study Patients
Treatment
(apart from cART)
CD4 counts
(cells/mm3)
Viral Load
(copies/mL)
Study 1 16 - Dendritic cell-based
HIV-vaccine (n=12)
- Placebo (n=4)
>500 (pre-cART) >5000 (pre-cART)
<20 for at least 104
weeks while receiving
cART
Study 2 35 - Dendritic cell-based
HIV-vaccine (n=24)
- Placebo (n=11)
>450 (baseline) <37 (enrollment)
Study 3 18 >350 (previous years)
>450 (at enrollment)
Undetectable at least
6 months before
inclusion
Study 4 11 - Received MMF (n=7)
- Did not (n=4)
>500 200-5000 (baseline)
Study 5 20 >500 (pre-cART) >5000 (pre-cART)
Study 6 28 - Ankara-based vaccine
and Gag-Pol-Nef polyprotein
with a drug to reactive latent
HIV (n=19)
- Placebo (n=9)
>450 Not specified
Study 7 33 >740 Undetectable for a
median of 21 months
Study 8 10 >500 (last 3 months) >10000
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